In people with no history of CV disease, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels can predict a higher risk of developing CV disease across various blood pressure and pulse pressure ...

Wanting more data on the benefits of sacubitril/valsartan vs renin angiotensin system inhibitor background therapy, investigators conducted a large randomized study among persons with heart failure ...

Please provide your email address to receive an email when new articles are posted on . Empagliflozin was safe and effective in patients with HF with reduced ejection fraction regardless of systolic ...

July 16, 2009 (Uppsala, Sweden) — N-terminal pro-brain natriuretic peptide (NT-proBNP) was the only one of a panel of biomarkers that added significant prognostic information to conventional risk ...

To make further progress in understanding the unique cardiac disease characteristics of patients with HFpEF and a normal NT-proBNP level and to better tailor treatment, future studies should ...

(HealthDay News) — For high-risk patients with heart failure and reduced ejection fraction (HFrEF), an amino-terminal pro-B-type natriuretic peptide (NT-proBNP)-guided treatment strategy does not ...

Please provide your email address to receive an email when new articles are posted on . Select adults with ischemic heart failure with reduced ejection fraction may derive benefit from an ...

December 14, 2009 (Basel, Switzerland) — A randomized trial of natriuretic-peptide–guided therapy for heart failure has stopped enrolling patients after an interim analysis showed that the strategy ...

Pharmacokinetics (PK) and pharmacodynamics (PD) in First-MIND: A phase Ib, open-label, randomized study of tafasitamab (tafa) ± lenalidomide (LEN) in addition to R-CHOP in patients (pts) with newly ...

RARITAN, N.J. -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, announced the CE Mark of an enhanced version of its VITROS® NT-proBNP II assay, part of Ortho's expansive cardiac ...